Eisai R&d Management Co., Ltd.

Eisai Company, Limited

Kogyoku Shin

Yoshinori Takahashi

Hisashi Shibata

Shigeki Hibi

Yorihisa Hoshino

Motohiro Soejima

Tatsuya Yoshiuchi

Mitsuhiro Ino

Koichi Kikuchi

Tetsuya Hirakawa

Mutsuko Ono

Toshihiko Kaneko

Koichi Ito

Koki Kawano

Noritaka Kitazawa

Kouichi Kikuchi

Teiji Kimura

Mamoru Takaishi

Hiroaki Hagiwara

Eriko Doi

Takehiko Miyagawa

Kunitoshi Takeda

Mutsuko Tabata

Taro Terauchi

Takeo Sasaki

Kodo Shikata

Akira Inomata

Minako Hashizume

Masae Fujisawa

Toru Watanabe

Takayuki Hida

Makoto Kotake

Shinsuke Hirota

Yu Yoshida

Yoichi Kita

Yoshiaki Ohashi

Takashi Fukuyama

Yoshihisa Kobayashi

Tomoyuki Shibuguchi

Yasuaki Kamada

Hironori Fukumoto

Toshiki Kurokawa

Compounds represented by formulae (I) to (XXII) or pharmaceutically acceptable salts thereof: 

Pyranodipyridine compound

A compound represented by the formula (I) or pharmacologically acceptable salt thereof exhibits an excellent CRF receptor antagonism wherein X is a nitrogen atom or CH; Ris -A-A; Ais a single bond or a C1-6 alkylene group; Ais a hydrogen atom, a C1-6 alkyl group or a C3-6 cycloalkyl group, etc.; Ris -A-A; Ais a single bond or a C1-6 alkylene group; Ais a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, a non-aromatic heterocyclic group, or a heteroaryl group, etc.; Ris a C1-6 alkyl group, a C3-6 cycloalkyl group, a C1-6 alkoxy group, a C3-6 cycloalkoxy C1-6 alkyl group, di-C1-6 alkyl amino group, a halogen atom, a cyano group, a formyl group, or a carboxyl group, etc; Ris a hydrogen atom or a C1-6 alkoxy group; Ris a halogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group; Ris a hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkylthio group, or a C1-6 alkyl sulfinyl group etc.; and Ris a C1-6 alkyl group, a C1-6 alkoxy group, or a C1-6 alkylthio group.

Pyrazolothiazole compound

A compound represented by the following formula (I), or salt thereof exhibits excellent CRF receptor antagonism, and sufficient pharmacological activity, safety and pharmacokinetic properties as a drug. 

[object Object]

The present invention relates to a compound represented by Formula (I): (wherein Arrepresents an imidazolyl group which may be substituted with 1 to 3 substituents; Arrepresents a pyridinyl group, a pyrimidinyl group, or a phenyl group which may be substituted with 1 to 3 substituents; Xrepresents (1) &#x2014;C&#x2261;C&#x2014; or (2) a double bond etc. which may be substituted; Rand Rrepresent, for example, a C1-6 alkyl group or C3-8 cycloalkyl group which may be substituted) or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents.

Cinnamide compound

The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula or a salt thereof. Wherein Rdenotes a hydrogen atom, a Calkyl group, a Calkoxy group and the like; Rdenotes a halogen atom, a cyano group, a nitro group, a Calkyl group, a Calkenyl group, Calkynyl group and the like; Rdenotes a Caromatic hydrocarbon cyclic group or a 5- to 14-membered aromatic heterocyclic group, each of which may have a substituent; and X, Y and X are independent of each other and each denotes N or CR(wherein Rdenotes a hydrogen atom, a halogen atom, a cyano group, a nitro group, an optionally halogenated Calkyl group and the like) and, in this case, at least two of X, Y and Z denote CR.

Imidazo[1,2-b]pyridazine compound

The present invention relates to a process for preparing a compound of formula (6a): wherein Arrepresents an imidazolyl group which may be substituted with 1 to 3 substituents shown below; Arrepresents a pyridinyl group, a pyrimidinyl group or a phenyl group which may be substituted with 1 to 3 substituents; and Rrepresents a group selected from certain substituents.

The present invention relates to a compound represented by Formula (I): (wherein Arrepresents an imidazolyl group which may be substituted with 1 to 3 substituents; Arrepresents a pyridinyl group, a pyrimidinyl group, or a phenyl group which may be substituted with 1 to 3 substituents; Xrepresents (1) &#x2014;C&#x2261;C&#x2014; or (2) a double bond etc. which may be substituted; Rand Rrepresent, for example, a C1-6 alkyl group or C3-8 cycloalkyl group which may be substituted) or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents. The object of the present invention is to find a therapeutic or preventive agent for diseases caused by A&#x3b2;. According to the present invention, a therapeutic or preventive agents for diseases caused by A&#x3b2; can be provided.

Compounds represented by the general formula: [wherein Rrepresents methoxy, ethyl, methylthio, etc., R, Rand Reach represent hydrogen, a halogen, etc., Rand Reach represent &#x2014;X&#x2014;X&#x2014;X(wherein Xrepresents a single bond or &#x2014;CO&#x2014;, Xrepresents a single bond, &#x2014;NR, etc. and Xand Reach represent hydrogen, Calkyl, etc.), and Ar represents phenyl, pyridyl, etc.], salts thereof and hydrates of the foregoing.

Pyrazolo[1,5-a]pyridines and medicines containing the same

A compound represented by the formula: [wherein Ris methoxy, methylthio, ethyl, etc.; Rand Rare each independently cyclopropylmethyl, (4-tetrahydropyranyl)methyl, etc.; and two of R, Rand Rare Calkoxy while the remaining one is methoxymethyl, etc.], a salt thereof, or a hydrate of the foregoing. This compound has excellent antagonism against corticotropin-releasing factor receptor.

7-phenylpyrazolopyridine compounds

Pyrazolo[1,5-a] pyridines and medicines containing the same

The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula, a pharmacologically acceptable salt thereof or hydrates thereof,wherein Ris a hydrogen atom, etc.; Ris a hydrogen atom, etc.; M' represents a hydrogen atom, a halogen atom or a Calkyl group; R&#x2032; represents a hydrogen atom or a Calkyl group; and W&#x2032; represents a phenyl group, pyridyl group, thienyl group, or furyl group, each being optionally substituted; and a pharmacologically acceptable salt thereof or hydrates thereof.

Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it

The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula, a pharmacologically acceptable salt thereof or hydrates thereof.Wherein A, B and D are the same as or different from each other and each represents a group represented by the formula &#x2014;(CRR)&#x2014; (wherein Rand Rare the same as or different from each other and each represents a Calkyl group etc.), &#x2014;NR&#x2014; (wherein Rrepresetns hydrogen etc.) etc.; E and G are the same as or different from each other and each represents a group represented by the formula &#x2014;(CRR)&#x2014; (wherein Rand Rare the same as or different from each other and each represents hydrogen etc.; and p represents an integer of 0, 1 or 2); J represents a carbon atom or nitrogen atom, each substituted with Calkyl group optionally substituted with a halogen atom, etc.; K and L are the same as or different from each other and each represents carbon atom or nitrogen atom; M means hydrogen, a halogen atom, an optionally substituted Calkyl group etc.; and the partial structuremeans a single or double bond.

Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same

Growing community of inventors

Tsukuba, Japan

Kogyoku Shin